Cart
sales@molnova.com
TAK-931
CAS No. 1330782-76-7
TAK-931( Simurosertib | TAK931 )
Catalog No. M11316 CAS No. 1330782-76-7
TAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 160 | In Stock |
|
| 5MG | 154 | In Stock |
|
| 10MG | 215 | In Stock |
|
| 25MG | 399 | In Stock |
|
| 50MG | 551 | In Stock |
|
| 100MG | 762 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTAK-931
-
NoteResearch use only, not for human use.
-
Brief DescriptionTAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM.
-
DescriptionTAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM; prevents the initiation of DNA replication during mitosis, which causes cell cycle arrest and induces apoptosis, demonstrates antiproliferative activity with cancer cell lines and tumor growth inhibition (TGI) in murine ectopic xenograft models. Colon Cancer,Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsSimurosertib | TAK931
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research AreaCancer
-
IndicationColon Cancer
Chemical Information
-
CAS Number1330782-76-7
-
Formula Weight341.433
-
Molecular FormulaC17H19N5OS
-
Purity>98% (HPLC)
-
SolubilityDMSO : 75 mg/mL 219.66 mM
-
SMILESO=C1C2=C(C=C(C3=CNN=C3C)S2)N=C([C@H]4N(CC5)CCC5C4)N1
-
Chemical NameThieno[3,2-d]pyrimidin-4(3H)-one, 2-(2S)-1-azabicyclo[2.2.2]oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Charles Locuson, et al. Abstract 5041: Translational pharmacokinetic-pharmacodynamic xenograft model for TAK-931, a small molecule cell division cycle 7 (CDC7) kinase inhibitor. AACR.
2. Kenichi Iwai, et al. Abstract 3073: Potential predictive biomarkers of clinical responses for a novel CDC7-selective inhibitor TAK-931. AACR.
molnova catalog
related products
-
LRRK2 inhibitor 1
LRRK2 inhibitor 1 is a selective and potent LRRK2 inhibitor with an IC50 of 13 nM.LRRK2 inhibitor 1 inhibits DCLK1 kinase with an IC50 value of 2.61 nM.
-
(R)-Enitociclib
(R)-Enitociclib, an enantiomer of BAY-1251152, is a CDK9 inhibitor with anticancer activity.
-
AT-7519
A potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).
